.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01F_MonoclonalAntibodiesAndAntibodyDrugConjugates.L01FX13_EnfortumabVedotin.EnfortumabVedotin .Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01F_MonoclonalAntibodiesAndAntibodyDrugConjugates.L01FX13_EnfortumabVedotin.EnfortumabVedotin| name: | EnfortumabVedotin | |
| ATC code: | L01FX13 | |
| route: | intravenous | |
| compartments: | 2 | |
| dosage: | 125 | mg |
| volume of distribution: | 7.5 | L |
| clearance: | 0.096 | L/h |
| other parameters in model implementation | ||
Enfortumab vedotin is an antibody-drug conjugate directed against Nectin-4, a protein highly expressed in urothelial cancers. It delivers the microtubule-disrupting agent monomethyl auristatin E (MMAE) selectively to tumor cells. It is approved for use in the treatment of adult patients with locally advanced or metastatic urothelial carcinoma who have previously received a PD-1 or PD-L1 inhibitor and platinum-containing chemotherapy.
Pharmacokinetic parameters reported in adult cancer patients (both male and female) with locally advanced or metastatic urothelial carcinoma after intravenous administration.